Very early molecular marker of tumor response to PD-1 inhibition in plasma of patients with advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Hiltermann, Thijo Jeroen Nicolaas
Miedema, A.
Hijmering-Kappelle, Lucie
Groen, Harry J. M.
Schuuring, Ed
机构：
[1] Univ Med Ctr Groningen, Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.3030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3030
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Expression and function of PD-1 and TIM-3 in non-small cell lung cancer (NSCLC)
    Travers, Jonathan
    McEachern, Krtisten
    Ghosh, Srimoyee
    Ramaswamy, Sridhar
    Jenkins, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [22] PD-L1 Expression in Circulating Tumor Cells and Response to PD-1 Inhibitor Treatment in Non-Small Cell Lung Cancer Patients
    Guibert, N.
    Delaunay, M.
    Boubekeur, N.
    Rouquette, I.
    Lusque, A.
    Clermont, E.
    Fortoul, A.
    Farella, M.
    Favre, G.
    Pradines, A.
    Mazieres, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1997 - S1997
  • [23] Patterns of disease progression in advanced non-small cell lung cancer patients treated with PD-1 inhibitors
    Qin, Angel
    Kalemkerian, Gregory Peter
    Schneider, Bryan J.
    Hassan, Khaled Aref
    Cease, Kemp Bailey
    Zhao, Lili
    Warren, Edus H.
    Ramnath, Nithya
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [24] Initial tumor flare or mixed tumor response following single PD-1 vs. dual PD-1/CTLA-4 blockade in non-small cell lung cancer (NSCLC).
    Chatwal, Monica Sheila
    Creelan, Ben C.
    Gray, Jhanelle Elaine
    Tanvetyanon, Tawee
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer
    Zhu, Lingling
    Lin, Jiewei
    Wang, Li
    Yan, Danli
    Zhou, Jie
    Li, Wen
    Pu, Dan
    Peng, Lei
    Zhou, Qinghua
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (04)
  • [26] Efficacy of PD-1 Inhibitors in Older Non-small Cell Lung Cancer Patients
    Nakamura, Yukiko
    Miyazaki, Kazuhito
    Aiko, Naoto
    Misumi, Yuki
    Agemi, Yoko
    Taniguchi, Yuri
    Ishi, Mari
    Shimokawa, Tsuneo
    Okamoto, Hiroaki
    Yamanaka, Takeharu
    ANTICANCER RESEARCH, 2020, 40 (02) : 923 - 928
  • [27] Tumor response dynamics of advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with commercial PD-1 inhibitors in the clinical setting.
    Nishino, Mizuki
    Dahlberg, Suzanne Eleanor
    Adeni, Anika E.
    Lydon, Christine A.
    Hatabu, Hiroto
    Janne, Pasi A.
    Hodi, F. Stephen
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Efficacy and safety of PD-1/PD-L1 inhibitors in elderly patients with advanced non-small cell lung cancer
    Li, Li
    Xu, Chunhua
    Wang, Wei
    Zhang, Qian
    CLINICAL RESPIRATORY JOURNAL, 2024, 18 (05):
  • [29] Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer
    Kim, Hye In
    Kim, Mijin
    Lee, Se-Hoon
    Park, So Young
    Kim, Young Nam
    Kim, Hosu
    Jeon, Min Ji
    Kim, Tae Yong
    Kim, Sun Wook
    Kim, Won Bae
    Kim, Sang-We
    Lee, Dae Ho
    Park, Keunchil
    Ahn, Myung-Ju
    Chung, Jae Hoon
    Shong, Young Kee
    Kim, Won Gu
    Kim, Tae Hyuk
    ONCOIMMUNOLOGY, 2018, 7 (01):
  • [30] Early but promising data: PD-1 inhibitors in non-small cell lung cancer.
    Garon, Edward B.
    Wolf, Brian R.
    Wong, Deborah J. L.
    Goldman, Jonathan W.
    CLINICAL CANCER RESEARCH, 2014, 20
12345